While women and men share the 3 most common risk factors for CVD—hypertension, high low-density lipoprotein-cholesterol (LDL-C), and smoking1, 5, 6—there are unique risk-enhancing factors for women at every stage of life.
Early identification of cardiovascular disease (CVD) risk in women can help save lives
CVD is the leading cause of death in women, taking the lives of over 300,000 women in the US in 2020.1
However, women are much less likely than men to be assessed for CVD risk based on guidelines.2
Many risk factors that are unique to women may be overlooked4
Testing solutions to help assess both traditional and risk-enhancing factors for CVD risk in women
Individuals suitable for testing:
- Patients with 1 or more traditional risk factors
- Patients with 1 or more risk-enhancing factors unique to women (see table above)
Testing solutions for early identification of CVD risk in women
Lipid screening assesses lipoprotein and apolipoprotein to improve risk stratification, allowing you to personalize patient treatment plans more precisely
Inflammation within the artery wall is a key contributor to CVD risk; monitoring inflammatory markers may help uncover hidden CVD risk
Identification of metabolic risk at an early stage allows implementation of evidence-based strategies that can prevent or delay disease progression
a Panel and profile components may be ordered separately:
Lipid Panel: Cardio IQ Cholesterol Total (91717); Cardio IQ Triglycerides (91718); Cardio IQ HDL Cholesterol (91719)
Lipid Panel with Reflex to Direct LDL: Cardio IQ Cholesterol Total (91717); Cardio IQ Triglycerides (91718); Cardio IQ HDL Cholesterol (91719). If triglyceride result is >400 mg/dL, Direct LDL Cholesterol will be performed at an additional charge
References
- CDC. Women and heart disease. Reviewed October 14, 2022. Accessed November 9, 2022. https://www.cdc.gov/heartdisease/women.htm
- Brown HL, et al. doi:10.1161/CIR.0000000000000582
- Bairey Merz CN, et al. doi:10.1016/j.jacc.2017.05.024
- Maffei S, et al. doi:10.1016/j.ijcard.2019.02.005
- Arnett DK, et al. doi:10.1161/CIR.0000000000000678
- Yusuf S, et al. doi:10.1016/S0140-6736(04)17018-9
- Lee JJ, et al. doi:10.1161/JAHA.119.012406
- Ayer J, et al. doi:10.1093/eurheartj/ehv089
- Solomon CG, et al. doi:10.1210/jcem.87.5.8471
- Lau ES, et al. doi:10.1016/j.jacc.2022.02.020
- Osibogun O, et al. doi:10.1016/j.tcm.2019.08.010
- Okoth K, et al. doi:10.1111/1471-0528.16692
- McIntyre HD, et al. doi:10.1038/s41572-019-0098-8
- Wu P, et al. doi:10.1161/JAHA.117.007809
- Wu P, et al. doi:10.1161/CIRCOUTCOMES.116.003497
- Okoth K, et al. doi:10.1136/bmj.m3502
- Carlson LE, et al. doi:10.1016/j.jaccao.2021.07.008
- Jurgens CY, et al. doi:10.1161/CIR.0000000000001089
- Moran, et al. doi:10.1161/CIRCRESAHA.121.319877
- Moon, et al. doi:10.1089/thy.2017.0414
- Razvi, et al. doi: 10.1016/j.jacc.2018.02.045
- Okoth K, et al. doi:10.1136/bmj.m3502
- Jiesuck Park, et al. doi:10.1136/heartjnl-2020-318764
- Brown JC, et al. doi:10.1002/jcsm.12073
- Barton M, et al. doi:10.1161/HYPERTENSIONAHA.108.120022
- Haring B, et al. doi:10.1161/JAHA.113.000369
- Tankó LB, et al. doi:10.1359/JBMR.050711
Risk assessment: women and cardiovascular disease
Read how the lab can help with testing for risk assessment, diagnosis, and management of CVD.
Cardiovascular disease
Cardiovascular disease
-
Advanced lipid testing -
Identifying residual risk -
Inflammation testing -
Advanced inflammatory marker testing -
Metabolic testing -
Metabolic testing portfolio -
Cardiogenetic testing -
Heart failure -
Focus on earlier identification of heart failure risk -
Non-lipid markers for CVD -
Important genotyping -
CVD test descriptions -
4myheart® program -
Cardio IQ® report -
Early identification of CVD risk in women
Save time & fix billing issues
Avoid disruptions and reduce paperwork with electronic billing trailers.
Raise patient satisfaction and get the insights you need
Access better patient tools, view test offerings, improve your bottom line, and more.
- Site map
- Privacy Notices
- Terms
- Contact us
- Language assistance / non-discrimination
- Asistencia de idiomas / Aviso de no discriminación
- 語言協助 / 不歧視通知
- Accessibility
-
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.